AVANIR Pharmaceuticals (AVNR)

16.96
0.00 (0.00)
NASDAQ : Health Care
Prev Close 16.96
Open 16.96
Day Low/High 16.96 / 16.98
52 Wk Low/High 3.02 / 17.05
Volume 8.44M
Avg Volume 6.29M
Exchange NASDAQ
Shares Outstanding 193.76M
Market Cap 3.29B
EPS -0.31
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NUEDEXTA® Effective For Pseudobulbar Affect (PBA) In Patients With Alzheimer's Disease And Other Dementias, Stroke And Traumatic Brain Injury

NUEDEXTA® Effective For Pseudobulbar Affect (PBA) In Patients With Alzheimer's Disease And Other Dementias, Stroke And Traumatic Brain Injury

-- PRISM II study published in BMC Neurology adds to clinical evidence demonstrating NUEDEXTA efficacy for PBA across diverse neurological disorders --

Avanir Pharmaceuticals Announces FDA Approval Of ONZETRA™ Xsail™ (AVP-825) For The Acute Treatment Of Migraine In Adults

Avanir Pharmaceuticals Announces FDA Approval Of ONZETRA™ Xsail™ (AVP-825) For The Acute Treatment Of Migraine In Adults

--ONZETRA Xsail is the first breath-powered intranasal medication delivery system for the acute treatment of migraine--

Avanir Pharmaceuticals Announces Publication Of Study Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms And Use Of Antipsychotic Medications In Nursing Homes

Avanir Pharmaceuticals Announces Publication Of Study Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms And Use Of Antipsychotic Medications In Nursing Homes

-- First Study to Evaluate the Prevalence of PBA Symptoms in Nursing Home Residents Found Almost 1 in 10 Residents Had Symptoms of PBA; These Patients with PBA Symptoms were Twice as Likely to Receive Antipsychotics --

Avanir Pharmaceuticals Announces Initiation Of Phase III Trial Of AVP-786 For Agitation In Patients With Alzheimer's Disease

Avanir Pharmaceuticals Announces Initiation Of Phase III Trial Of AVP-786 For Agitation In Patients With Alzheimer's Disease

-- AVP-786 Granted FDA Fast Track Designation for This Indication --

Avanir Pharmaceuticals Announces New Findings From Dementia/Alzheimer's Disease Cohort Of PRISM II Study At Alzheimer's Association International Conference

Avanir Pharmaceuticals Announces New Findings From Dementia/Alzheimer's Disease Cohort Of PRISM II Study At Alzheimer's Association International Conference

--New Data Demonstrate Treatment Effects on Pseudobulbar Affect (PBA) with NUEDEXTA Regardless of Concomitant Antidepressant Use--

Avanir Pharmaceuticals Announces Positive Top-line Results From Stroke And TBI Cohorts Of PRISM II Study

Avanir Pharmaceuticals Announces Positive Top-line Results From Stroke And TBI Cohorts Of PRISM II Study

-- Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in PBA Patients Who Had an Underlying Stroke or Traumatic Brain Injury --

Avanir Pharmaceuticals Announces Presentation Of Survey Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms In Retired Professional Football Players At The 12th Annual North American Brain Injury Society Conference

Avanir Pharmaceuticals Announces Presentation Of Survey Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms In Retired Professional Football Players At The 12th Annual North American Brain Injury Society Conference

-- Ninety nine percent of respondents experienced some form of brain trauma during their playing career and one third also report symptoms of PBA --

Danny Glover Joins PBA Facts Campaign, To Educate And Build Awareness Of Pseudobulbar Affect (PBA), A Little Known But Widespread Neurologic Condition

Danny Glover Joins PBA Facts Campaign, To Educate And Build Awareness Of Pseudobulbar Affect (PBA), A Little Known But Widespread Neurologic Condition

--Avanir Pharmaceuticals Takes Unique Approach to Patient Education in New Initiative--

Develop Biotech 'Buy-Sell' Strategy

When to take profits is a tricky but important decision.

Two Small-Cap Biotechs To Consider

Fibrocell Science and Prothena have several 'shots on goal.'

Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused By Brain Injury

Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused By Brain Injury

'Tackle PBA,' a New Educational Campaign, Addresses Why Many Former Pro Football Players Cry or Laugh Uncontrollably with Little to No Clear Trigger

Next Year's Stock Returns: 5% or 15%?

Returns could be within this range in 2015.

Updating a Small Speculative Play

Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The

Three Large-Cap Growth Stocks

I would pick up some large caps on any significant dips.

Through Laughter And Tears Comes First-Ever Documentary About Life With PseudoBulbar Affect (PBA)

Through Laughter And Tears Comes First-Ever Documentary About Life With PseudoBulbar Affect (PBA)

--Award-Winning Filmmakers Capture Untold Story of Little-Known Neurologic Condition That Affects Nearly 2 Million Americans--